HC Wainwright & Co. Reiterates Buy on ProQR Therapeutics, Maintains $5 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on ProQR Therapeutics (NASDAQ:PRQR) and maintained a $5 price target.
August 07, 2023 | 10:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ProQR Therapeutics has received a reiterated 'Buy' rating and a maintained $5 price target from HC Wainwright & Co.
The reiterated 'Buy' rating and maintained $5 price target by HC Wainwright & Co. indicates a positive outlook for ProQR Therapeutics. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100